Navigation Links
Biomarkers May Help Measure Rate of Decline in Dementia
Date:5/12/2009

Cerebrospinal fluid could be key in improving Alzheimer's research

TUESDAY, May 12 (HealthDay News) -- Checking levels of certain biomarkers in cerebrospinal fluid may help predict the rate of cognitive decline in people with very mild dementia, and this information could be used to improve the effectiveness of clinical trials, say U.S. researchers.

Their study, published in the May issue of the journal Archives of Neurology, included 49 people who'd been diagnosed with very mild Alzheimer's disease. Samples of cerebrospinal fluid taken from the patients were tested for several biomarkers associated with Alzheimer's, including alpha-beta peptide 1-42 (Aβ42), tau, and phosphorylated tau 181 (ptau 181).

The patients had at least one follow-up assessment an average of 3.5 years later and the researchers found that the "rate of dementia progression was significantly more rapid in individuals with lower baseline cerebrospinal fluid Aβ42 levels, higher tau or ptau 181 levels or high tau:Aβ42 ratios."

Finding effective treatments for Alzheimer's will likely depend on early identification of patients, noted study author Dr. Barbara J. Snider and colleagues at Washington University School of Medicine in St. Louis.

"Because there is a growing emphasis on enrolling individuals with less cognitive impairment into clinical trials of [possible] anti-Alzheimer's disease agents, methods are needed that will identify individuals with very mild dementia of the Alzheimer's type who are more likely to exhibit measurable cognitive decline during the study," the researchers wrote.

"Although the number of participants in this study was relatively small, the results suggest that cerebrospinal fluid biomarkers might be useful as entry criteria for clinical trials of disease-modifying therapies for mild cognitive impairment and very mild dementia of the Alzheimer type," they noted.

The study findings may "have important implications for reducing the number of participants needed to show an effect in clinical trials for very mild dementia of the Alzheimer type and mild cognitive impairment and, ultimately, to assist in making treatment decisions as more invasive and potentially harmful disease-modifying treatments for Alzheimer's disease become available," the authors concluded.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about dementia.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, May 11, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Biomarkers predict risk for invasive breast cancer years before the tumor develops
4. JDRF and Lilly partner to fund research to identify beta cell biomarkers
5. Biomarkers for Alzheimers disease can be trusted in clinical trials
6. New developments in biomarkers for epithelial ovarian cancer
7. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
8. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
9. Biomarkers for Mood May Alter Psychiatric Treatments
10. Biomarkers and Innovation Push Global Cancer Diagnostics Market Toward $8 Billion
11. Scientists: New technique identifies molecular biomarkers for disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarkers May Help Measure Rate of Decline in Dementia
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... 2017 , ... In 1987, McDaniel & Durrett, P.C., a ... this year, and they’re marking the milestone by undertaking a significant office makeover, ... , It stands to reason that, given the central importance of gynecology to ...
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , a ... today announced Cumberland Skin Surgery and Dermatology has joined the company ... in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer ...
(Date:8/16/2017)... Island, NY (PRWEB) , ... August 16, 2017 , ... ... with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical ... takes much of the guesswork out of a needle stick and more importantly, helps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, ... Connolly 2017 Top Doctor. The annual list identifies the nation’s top physicians, in a ... has made it to the top of Castle Connolly’s coveted ranking. , Castle Connolly ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017 AccuGenomics, Inc., a diagnostic ... today announced that the company has provided an AccuKit ... North Carolina at Chapel Hill and to Qura Therapeutics ... characterize and quantify HIV reservoir and viral expression in ... The HIV Cure Center is a joint initiative between ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/10/2017)... 10, 2017  Physical Rehabilitation Network (PRN), acquired the long-standing ... Lakewood, Colorado . The reputable clinic will continue to ... DPT with his staff of four clinicians. Lipkin received his ... brings over 10 years of experience with a strong background ... PT marks the 10th PRN clinic in and around the ...
Breaking Medicine Technology: